Recently, some clinicians have employed a combination of CEA, CA19-9, cytokeratin-1 (CK-1), CA72-4 and mucin-1 (MUC-1) to predict unfavorable outcomes in gastrointestinal tumors, which has improved the sensitivity and specificity of tumor surveillance while also evaluating tumor stage and metastasis (Pua et al., 2020). This evidence concerns the gene MUC1 and digestive system neoplasm.